RE:Francois' comments would be appreciatedI think Ccpatrader answered well the question. For me, it's make no doubt that PLI (and us as shareholders) Worth much more by getting the majority of Nantpro. Gain on paper for that transaction, like lost on paper for the value of warrants don't impressed me much. What impressed me, is the turnover in the last 2 years this company did, with fair equity financing, Laval up and running, and the turn around for the orphan drug strategy. Now PLI can, and have ceased to act on short term for small revenues, and heading more on mid and long term strategy, by creating much more value. The quaterly results means not much for me, but seeing that we will be a future drug manufacturer in orphan disease with the plasma proteins and maybe also in fibrosis with PBI-4050, is what I like. Intermune have a market cap of $ 5.6B with Esbriet. So imagine PLI with 5-6 orphan drugs, and 4050 with better results than Esbriet...